{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-008145","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2025-05-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.621384+00:00","generated_at":"2026-05-20T10:13:40.082397+00:00","sec_items":["5.02","5.07"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Capricor stockholders approve 2025 Equity Incentive Plan (3.5M shares plus 5% annual increase)","bullets":["Stockholders approved 2025 Equity Incentive Plan (3.5M shares reserved) with ~54% of votes cast in favor (9.7M FOR, 8.2M AGAINST).","Plan includes annual evergreen increase of 5% of outstanding shares from 2026 through 2035.","Rose, Snyder & Jacobs LLP ratified as independent auditor for FY2025.","Say-on-pay advisory vote passed with ~92% in favor (16.4M FOR, 1.5M AGAINST).","30.55M shares present (66.9% of outstanding) at annual meeting on May 22, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-008145","json":"https://secwatch.observer/filing/0001558370-25-008145.json","markdown":"https://secwatch.observer/filing/0001558370-25-008145.md","text":"https://secwatch.observer/filing/0001558370-25-008145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837025008145/0001558370-25-008145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837025008145/capr-20250522x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T10:13:40.082397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}